Pralsetinib: A Targeted Therapy for RET-Driven Cancers
Pralsetinib is a targeted therapy medication used to treat certain types of cancer driven by the RET gene. It works by blocking the activity of the RET protein, which is involved in the growth and survival of cancer cells.
Approved Uses:
- Non-small cell lung cancer: Pralsetinib is approved for the treatment of non-small cell lung cancer (NSCLC) patients with RET gene fusions.
- Medullary thyroid cancer: It is also indicated for the treatment of advanced or metastatic medullary thyroid cancer (MTC).
Working:
- RET Inhibition: Pralsetinib selectively targets the RET protein, preventing its activation and
- signaling pathways that promote cancer cell growth and survival.
- Tumor Shrinkage: By inhibiting RET,
- pralsetinib can lead to the shrinkage of tumors and improve patient outcomes.